Safety and tolerability of lumbar puncture for the evaluation of Alzheimer's disease

被引:3
|
作者
Baldaranov, Dobri [1 ]
Garcia, Victoria [1 ]
Miller, Garrett [1 ]
Donohue, Michael C. [1 ]
Shaw, Leslie M. [2 ]
Weiner, Mike [3 ,4 ,5 ,6 ,7 ]
Petersen, Ronald C. [8 ]
Aisen, Paul [1 ]
Raman, Rema [1 ]
Rafii, Michael S. [1 ]
机构
[1] Univ Southern Calif, Alzheimers Therapeut Res Inst, San Diego 9860 Mesa Rim Rd, San Diego, CA 92121 USA
[2] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA USA
[3] Ctr Imaging Neurodegenerat Dis, Dept Vet Affairs Med Ctr, San Francisco, CA USA
[4] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA USA
[5] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[6] Univ Calif San Francisco, Dept Psychiat & Behav Sci, San Francisco, CA USA
[7] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA
[8] Mayo Clin, Dept Neurol, Mayo Clin Study Aging, Mayo Clin Neurol & Neurosurg,Alzheimers Dis Res Ct, Rochester, MN USA
基金
美国国家卫生研究院;
关键词
adverse effects; Alzheimer's disease; biomarker; brain volume; cerebrospinal fluid; lumbar puncture; pain relief medication; MULTICENTER; BIOMARKERS;
D O I
10.1002/dad2.12431
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
IntroductionLumbar puncture (LP) to collect and examine cerebrospinal fluid (CSF) is an important option for the evaluation of Alzheimer's disease (AD) biomarkers but it is not routinely performed due to its invasiveness and link to adverse effects (AE). MethodsWe include all participants who received at least one LP in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Study. For comparison between groups, two-sample t-tests for continuous, and Pearson's chi-square test for categorical variables were performed. ResultsTwo hundred twenty-seven LP-related AEs were reported by 172 participants after 1702 LPs (13.3%). The mean age of participants who reported at least one AE was 69.79 (standard deviation (SD) 6.3) versus none 72.44 (7.17) years (p < 0.001) with female predominance (115/172 = 67.4% vs 435/913 = 48%), and had greater entorhinal cortical thickness and hippocampal volume (3.903 (0.782) vs 3.684 (0.775) mm, p = 0.002; 7.38 (1.06) vs 7.05 (1.15) mm(3), p < 0.001), respectively. DiscussionWe found that younger age, female sex, and greater thickness of the entorhinal cortex were associated with a higher rate of LP-related AE reports.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Safety of Lumbar Puncture Procedures in Patients with Alzheimer's Disease
    Peskind, E.
    Nordberg, A.
    Darreh-Shori, T.
    Soininen, H.
    CURRENT ALZHEIMER RESEARCH, 2009, 6 (03) : 290 - 292
  • [2] The use of lumbar puncture and safety recommendations in Alzheimer's disease: a plain language summary
    Hampel, Harald
    Elhage, Aya
    Shaw, Leslie M.
    Aisen, Paul
    Chen, Christopher
    Lleo, Alberto
    Iwatsubo, Takeshi
    Iwata, Atsushi
    Yamada, Masahito
    Ikeuchi, Takeshi
    Jia, Jianping
    Wang, Huali
    Teunissen, Charlotte E.
    Peskind, Elaine
    Blennow, Kaj
    Cummings, Jeffrey
    Vergallo, Andrea
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2022, 12 (05) : 221 - 229
  • [3] Donepezil: Tolerability and safety in Alzheimer's disease
    Pratt, RD
    Perdomo, CA
    Surick, IW
    Ieni, JR
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2002, 56 (09) : 710 - 717
  • [4] Safety and Tolerability of Research Lumbar Puncture in Huntington Disease: the HDClarity Cohort and Community Bioresource
    Rodrigues, Filipe B.
    Ehrhardt, Anka
    Owen, Gail
    Gosling, Stef
    Lifer, Sherry
    Neacy, Eileen
    Kaur, Dipinder
    Handley, Olivia
    Townhill, Jenny
    Leavitt, Blair
    Guttman, Mark
    Bang, Jee
    Levey, Jamie
    Pak, Elena
    Sampaio, Cristina
    Wild, Edward J.
    NEUROTHERAPEUTICS, 2018, 15 (04) : 1171 - 1171
  • [5] Comparative safety and tolerability of Alzheimer's disease treatments
    Alva, G.
    Olin, J. T.
    Resnick, E. M.
    Tocco, M.
    Graham, S. M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 : 184 - 184
  • [6] The safety and tolerability of donepezil in patients with Alzheimer's disease
    Jackson, S
    Ham, RJ
    Wilkinson, D
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 : 1 - 8
  • [7] Comparative Safety and Tolerability of Alzheimer's Disease Treatments
    Alva, Gustavo
    Cummings, Jeffrey L.
    Resnick, Malca
    Tocco, Michael
    Graham, Stephen
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2008, 16 (03): : A109 - A110
  • [8] Factors Associated with Lumbar Puncture Participation in Alzheimer's Disease Research
    Blazel, Madeleine M.
    Lazar, Karen K.
    Van Hulle, Carol A.
    Ma, Yue
    Cole, Aleshia
    Spalitta, Alice
    Davenport-Sis, Nancy
    Bendlin, Barbara B.
    Wahoske, Michelle
    Illingworth, Chuck
    Gleason, Carey E.
    Edwards, Dorothy F.
    Blazel, Hanna
    Asthana, Sanjay
    Johnson, Sterling C.
    Carlsson, Cynthia M.
    JOURNAL OF ALZHEIMERS DISEASE, 2020, 77 (04) : 1559 - 1567
  • [9] Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease
    Turner, Raymond S.
    Hebron, Michaeline L.
    Lawler, Abigail
    Mundel, Elizabeth E.
    Yusuf, Nadia
    Starr, J. Nathan
    Anjum, Muhammad
    Pagan, Fernando
    Torres-Yaghi, Yasar
    Shi, Wangke
    Mulki, Sanjana
    Ferrante, Dalila
    Matar, Sara
    Liu, Xiaoguang
    Esposito, Giuseppe
    Berkowitz, Frank
    Jiang, Xiong
    Ahn, Jaeil
    Moussa, Charbel
    ANNALS OF NEUROLOGY, 2020, 88 (01) : 183 - 194
  • [10] Rivastigmine and Concomitant Memantine in Alzheimer's Disease: Safety and Tolerability
    Safirstein, Beth
    Meng, Xiangyi
    Olin, Jason T.
    CNS SPECTRUMS, 2010, 15 (09) : 594 - 598